Brussels, 5 July 2021
From micro-organism production of the world’s vitamin B2, a revolution in cancer therapy using our own immune systems, and the first Covid mRNA vaccine approved – these are just a few examples of the selected landmarks in biotechnology that were officially announced today as the start of EuropaBio’s 25th Anniversary programme.
To mark a quarter century of impactful biotechnology since EuropaBio launch, members have been nominating important scientific, industry and ecosystem developments that shape our lives now. Today sees publication of almost 30 nominations in the first wave received from Members, with over 50 anticipated by the end of anniversary celebrations in 2021. They recognise brilliant science, innovative companies beakthroughs and a European landscape that enabled new medicines and novel materials.
‘I am thrilled that we received so many excellent nominations from Members, and these show us that biotechnology impacts so many aspects of our lives. Behind every headline product, are decades of scientific advance from researchers and innovators in the public and private sector. They are, in turn, enabled by the collaborative landscape that Europe has built across borders to amplify strengths and grow together. Our 25th anniversary is a great opportunity not only to celebrate these achievements but also to gather the community and look ahead to the next 25 years.’, says Dr Claire Skentelbery, Director General of EuropaBio.
The anniversary nominations will be amplified through webinars, interviews, conversations on social media discussing some of the key drivers that made them a reality. The year will end with a gala evening in Brussels recognising the best healthcare and industrial biotechnology advances from the anniversary. The ceremony will be followed by a presentation of the 2021 SME Award from EuropaBio, looking to the next generation of landmark biotechnology innovation.